 |
Register Now!    Release date: June 25, 2009 Expiration date: June 24, 2010 |
Program Description
The development of targeted therapies has improved treatment efficacy and quality-of-life for patients with advanced renal cell carcinoma. However, targeted therapies also present new clinical challenges. Early detection and management of physical and psychological side effects is important in maximizing patients’ quality-of-life. In this CME-certified program, Ms. Nancy Moldawer reviews the side effects associated with the targeted agents used in advanced RCC and describes how clinicians can best monitor for, and manage, these adverse events. Ms. Moldawer also covers issues of treatment interruption, discontinuation, and dose modification. Dr. Robert Figlin then discusses the challenging decisions of when to switch therapies and when a referral may be appropriate.
Target Audience
This activity has been designed for community oncologists and nurses who provide care and support to patients with advanced RCC.
Learning Objectives
As a result of participating in the activity, participants will be better able to
Faculty
Robert A. Figlin, MD (Activity Director)
Arthur and Rosalie Kaplan Chair in Oncology
Professor and Chair, Medical Oncology and Therapeutics Research
City of Hope National Medical Center and Beckman Research Institute
Associate Director for Clinical Research
City of Hope National Medical Center
Duarte, California
Nancy P. Moldawer, RN, MSN
Clinical Research Operations Manager
Acting Director, Clinical Trials Office
Department of Medical Oncology and Experimental Therapeutics
City of Hope National Medical Center
Duarte, California
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the City of Hope and Alliance Medical Communications. The City of Hope is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
The City of Hope designates this educational activity for 1 AMA Physicians’ Recognition Award™ credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure
City of Hope takes responsibility for the content, quality and scientific integrity of this continuing medical education (CME) activity. Prior to their participation in this City of Hope CME activity, all faculty/presenters have disclosed any real or apparent vested commercial interest(s) in both those companies whose products may be discussed during the course of the activity and in those companies acting as commercial supporters of the activity. City of Hope further requires that prior to the activity, faculty/presenters have disclosed their intention to discuss any off-label and/or investigational (not yet approved for any purpose) use of pharmaceuticals or medical devices. Written disclosure of faculty/presenters’ specific commercial relationships and/or intent to discuss off-label and/or investigational is provided below.
Robert A. Figlin, MD (Activity Director)
Nancy P. Moldawer, RN, MSN
Independent Clinical Peer Reviewer
Robert J. Morgan Jr., MD
Director, Continuing Medical Education
Associate Director for Education
Department of Oncology and Therapeutics Research
City of Hope National Medical Center
Duarte, California
Planning Committee
Crystal Saavedra, City of Hope National Medical Center and Deborah Dean, Mindy Tanzola, PhD, and Michelle Yechout, Alliance Medical Communications: No relevant financial relationships with any commercial interests.
Off-label Use
The following is a list of specific mention of off-label and/or investigational use of products within all presentations.
References
The development of targeted therapies has improved treatment efficacy and quality-of-life for patients with advanced renal cell carcinoma. However, targeted therapies also present new clinical challenges. Early detection and management of physical and psychological side effects is important in maximizing patients’ quality-of-life. In this CME-certified program, Ms. Nancy Moldawer reviews the side effects associated with the targeted agents used in advanced RCC and describes how clinicians can best monitor for, and manage, these adverse events. Ms. Moldawer also covers issues of treatment interruption, discontinuation, and dose modification. Dr. Robert Figlin then discusses the challenging decisions of when to switch therapies and when a referral may be appropriate.
Target Audience
This activity has been designed for community oncologists and nurses who provide care and support to patients with advanced RCC.
Learning Objectives
As a result of participating in the activity, participants will be better able to
| • | Describe the adverse events associated with targeted therapies | |
| • | Improve patients’ quality-of-life by effectively detecting and managing adverse effects associated with targeted therapy | |
| • | Decide whether targeted therapy should be continued, interrupted, or discontinued, based on side effects |
Faculty
Robert A. Figlin, MD (Activity Director)
Arthur and Rosalie Kaplan Chair in Oncology
Professor and Chair, Medical Oncology and Therapeutics Research
City of Hope National Medical Center and Beckman Research Institute
Associate Director for Clinical Research
City of Hope National Medical Center
Duarte, California
Nancy P. Moldawer, RN, MSN
Clinical Research Operations Manager
Acting Director, Clinical Trials Office
Department of Medical Oncology and Experimental Therapeutics
City of Hope National Medical Center
Duarte, California
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the City of Hope and Alliance Medical Communications. The City of Hope is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
The City of Hope designates this educational activity for 1 AMA Physicians’ Recognition Award™ credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure
City of Hope takes responsibility for the content, quality and scientific integrity of this continuing medical education (CME) activity. Prior to their participation in this City of Hope CME activity, all faculty/presenters have disclosed any real or apparent vested commercial interest(s) in both those companies whose products may be discussed during the course of the activity and in those companies acting as commercial supporters of the activity. City of Hope further requires that prior to the activity, faculty/presenters have disclosed their intention to discuss any off-label and/or investigational (not yet approved for any purpose) use of pharmaceuticals or medical devices. Written disclosure of faculty/presenters’ specific commercial relationships and/or intent to discuss off-label and/or investigational is provided below.
Robert A. Figlin, MD (Activity Director)
| Commercial Interest | Relationship |
| Aveo Pharmaceuticals | Consultant |
| Amgen, Argos Therapeutics, Antisoma plc, Novartis AG; Pfizer Inc |
Grant/Research Support |
Nancy P. Moldawer, RN, MSN
| Commercial Interest | Relationship |
| Novartis AG; Pfizer Inc; Wyeth | Speakers’ Bureau |
Independent Clinical Peer Reviewer
Robert J. Morgan Jr., MD
Director, Continuing Medical Education
Associate Director for Education
Department of Oncology and Therapeutics Research
City of Hope National Medical Center
Duarte, California
Planning Committee
Crystal Saavedra, City of Hope National Medical Center and Deborah Dean, Mindy Tanzola, PhD, and Michelle Yechout, Alliance Medical Communications: No relevant financial relationships with any commercial interests.
Off-label Use
The following is a list of specific mention of off-label and/or investigational use of products within all presentations.
| Product | Investigational and/or Off-Label Use |
| Bevacizumab | Renal cell carcinoma |
| HD IL-2 | Renal cell carcinoma |
| IFN | Renal cell carcinoma |
| Perifosine | Renal cell carcinoma |
References
| 1. | Afinitor® prescribing information. Accessed April 2009. Available at http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf. |
| 2. | Anderson R, Jatoi A, Robert C, et al. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist. 2009;14(3):291-302. |
| 3. | Atkins MB. ASCO 2006 Plenary session. |
| 4. | Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005;11(10):3714-3721. |
| 5. | Avastin® full prescribing information, Genentech, Inc. Accessed February, 2009. Available at http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf. |
| 6. | Cho D, Signoretti S, Regan M et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 2007;13(2 pt 2):758s. |
| 7. | Escudier B. Advanced renal cell carcinoma: current and emerging management strategies. Drugs; 2007;67(9):1257-1264. |
| 8. | Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-2111. |
| 9. | Figlin RA. Newly approved therapies for RCC and their effect on the standard of care. Clin Adv Hematol Oncol. 2007;5(1):35-36, 66. |
| 10. | Garcia JA. 7th International Kidney Cancer Symposium. 2008. |
| 11. | Herrmann E, Gerss J, Bierer S et al. Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib. J Cancer Res Clin Oncol. 2009;135(1):61-67. |
| 12. | Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281. |
| 13. | Hutson TE, Figlin RA, Kuhn JG et al. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008;13(10):1084-1096. |
| 14. | Ignoffo RJ. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm. 2004;61(21 Suppl 5):S21-26. |
| 14. | Ignoffo RJ. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm. 2004;61(21 Suppl 5):S21-26. |
| 15. | Moldawer N, Wood LS. Integrating the Oncology Nurse Into the New Paradigm of Targeted Therapy in Renal Cell Cancer: Special Considerations, Initiatives, and Guidelines. Kidney Cancer Journal. 2006; 4(1):25-32. |
| 16. | Moore SH. Online educational activity – 2006. |
| 17. | Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124. |
| 18. | Nexavar® full prescribing information, Bayer HealthCare. Accessed February, 2009. Available at http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf. |
| 19. | Peters L, Sellick K. Quality of life of cancer patients receiving inpatient and home-based palliative care. J Adv Nurs. 2006;53(5):524-533. |
| 20. | Rini BI, Halabi S, Rosenberg JE, Stadler WM, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422-5428. |
| 21. | Sutent® full prescribing information, Pfizer Inc. Accessed February, 2009. Available at http://www.pfizer.com/files/products/uspi_sutent.pdf. |
| 22. | Torisel® full prescribing information, Wyeth. Accessed February, 2009. Available at http://www.wyeth.com/hcp/torisel/prescribing-information. |
| 23. | Wood LS. Targeted Therapies for Advanced Renal Cell Carcinoma: Part I - Sunitinib. Oncology Nursing News. 2007;1(3):19-26. |
| 24. | Wood LS. Targeted Therapies for Advanced Renal Cell Carcinoma: Part II - Sorafenib. Oncology Nursing News. 2007;1(4):37-38. |